By Finance Pulse in KeyInfo —

H.C. Wainwright Upgrades Rapt Therapeutics on New Licensing Deal

Rapt Therapeutics receives a boost as H.C. Wainwright upgrades it to Buy following a new licensing agreement for an anti-immunoglobulin E monoclonal antibody.

A dynamic and futuristic depiction of molecules and antibodies, symbolizing biotechnology innovation
H.C. Wainwright Upgrades Rapt Therapeutics on New Licensing Deal

H.C. Wainwright upgraded Rapt Therapeutics to Buy due to a new licensing agreement for an anti-immunoglobulin E monoclonal antibody.

Source